Episode 50

Biotech AI Strategy: Why Most Pharma AI Projects Fail & How to Fix It? ( ft.Rose LaRocca-Fisch)

AI is moving incredibly fast across the life sciences sector, but many organizations still struggle to build systems that deliver real operational value. In this episode, tech leader Rose LaRocca-Fisch explains why strong data governance and business alignment must come before chasing software trends. Please visit our website to get more information: https://swangroup.net/

Rose shares her practical leadership experience guiding pharmaceutical companies, CDMOs, and global biotech organizations through massive growth. The discussion breaks down why high-profile tech implementations collapse and outlines the exact steps needed to prepare your infrastructure for enterprise-grade tools.

Key themes covered in this conversation:

✅Why does advanced software amplify existing operational flaws instead of fixing them

✅The OASIS framework for sustainable and scalable IT transformation

✅How data readiness directly impacts clinical trial success and manufacturing yields

✅Real-world applications using platforms like Databricks to speed up patient enrollment

✅The shift toward AI-assisted work and managing data integrity risks

Links from this episode:

✅Get to know more about Steven Swan: https://www.linkedin.com/in/swangroup

✅Get to know more about Rose LaRocca-Fisch: https://www.linkedin.com/in/rose-larocca-fisch

==== TIME STAMPS ====

00:00 – Introduction

04:24 – Why AI amplifies both strong and weak operational foundations